Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, has selected Ginolis Ltd, a global supplier of automation solutions, to deliver Ginolis’ Lateral Flow Device Assembly (LFDA) system to their manufacturing headquarters in Medford, N.Y..
The Ginolis Lateral Flow Device Assembly (LFDA) system is a compact solution that provides cost efficient assembly of rapid tests with high quality assurance. Based on Ginolis’ modular Xanthia automation platform, the LFDA is easily adaptable and can assemble different lateral flow devices with minimal product specific adjustments. Machine vision guidance and quality control throughout the entire system ensures a consistent high quality assembled device. The system will be used to automate assembly of Chembio’s patented Dual Path Platform (DPP®) technology, which offers improved performance (sensitivity & specificity) over traditional lateral flow technology, as well as simultaneous detection capabilities of both antigen and antibody in a disposable rapid test format.
Ginolis VP Sales and Marketing, Jorma Venäläinen, says “Ginolis sees intelligent automation as the future of diagnostics production. By being able to assemble multiple products with the same system, manufacturers save valuable space in their clean room environments. We are excited about working together with Chembio and delivering the first six module LFDA to USA.”
Jorma Venäläinen, VP Sales and Marketing
+358 50 365 7186 | firstname.lastname@example.org
Vida Strategic Partners (investor relations)
Stephanie C. Diaz | (415) 675-7401 | email@example.com
Ginolis specializes in providing high-quality automation and liquid handling solutions for the production and processing of healthcare consumables. The company is privately owned and headquartered in Oulu, Finland, with offices in Uppsala, Sweden, San Diego, USA and Suzhou, China. For more information please visit www.ginolis.com
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets rapid diagnostic tests in the growing $8.0 billion POC testing market. The Company markets its products directly and through third-party distributors under the brand names: DPP®, STAT-PAK® and SURE CHECK®
Chembio has developed and patented the DPP® technology platform, which offers significant advantages over traditional POC lateral-flow technologies and provides the Company with a significant pipeline of business opportunities in the area of sexually transmitted disease, tropical and fever disease, and technology collaborations.
Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Each of Chembio Diagnostic Systems, Inc. and RVR Diagnostics Sdn Bhd is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com.
Image: Ginolis Lateral Flow Device Assembly (LFDA) System